Nuuron–SEVERAL: investment, 202410 seed financing round €3.5m led by HTGF |
2024-10-31 |
Aignostics–Berlin (govt): investment, 202410 financing round Series B totalling $34m incl existing + co-investor VC Fonds Technologie |
2024-10-29 |
Aignostics–Boehringer: investment, 202410 financing round Series B totalling $34m incl existing + co-investor BIVF |
2024-10-29 |
Aignostics–Carma Fund: investment, 202410 financing round Series B totalling $34m incl existing + co-investor Carma Fund |
2024-10-29 |
Aignostics–High-Tech Gründerfonds: investment, 202410 financing round Series B totalling $34m incl existing + co-investor HTGF |
2024-10-29 |
Aignostics–Mayo Clinic: AI-based diagnostics, 202410 collab developm foundation models for digital pathology |
2024-10-29 |
Aignostics–Mayo Clinic: investment, 202410 financing round Series B totalling $34m incl co-investor Mayo Clinic |
2024-10-29 |
Aignostics–SEVERAL: investment, 202410 financing round Series B $34m led by Athos |
2024-10-29 |
Aignostics–Strüngmann Group: investment, 202410 financing round Series B totalling $34m incl lead investor Athos |
2024-10-29 |
Aignostics–Wellington Partners: investment, 202410 financing round Series B totalling $34m incl existing + co-investor Wellington Partners |
2024-10-29 |
Inbrain Neuroelectronics–SEVERAL: investment, 202410 financing round Series B $50m led by imec.xpand |
2024-10-29 |
Kynos Therapeutics–Falk Pharma: investment, 202410 acquisition of Kyno Therapeutics Ltd by Dr Falk Pharma GmbH |
2024-10-29 |
Kivu Bioscience–BioGeneration Ventures: investment, 202410 financing round Series A totalling $92m incl existing + co-investor BGV |
2024-10-28 |
Kivu Bioscience–Gimv: investment, 202410 financing round Series A totalling $92m incl new + co-investor Gimv |
2024-10-28 |
Kivu Bioscience–Lonza: ADC technology, 202410 existent use of GlycoConnect platform fo Synaffix by Kivu Bioscience |
2024-10-28 |
Kivu Bioscience–Merck (DE): investment, 202410 financing round Series A totalling $92m incl existing + co-investor M Ventures |
2024-10-28 |
Kivu Bioscience–Netherlands (govt): investment, 202410 financing round Series A totalling $92m incl existing + co-investor BOM |
2024-10-28 |
Kivu Bioscience–Novo Group: investment, 202410 financing round Series A totalling $92m incl lead investor Novo Holdings |
2024-10-28 |
Kivu Bioscience–Odlander Fredrikson: investment, 202410 financing round Series A totalling $92m incl new + co-investor HealthCap |
2024-10-28 |
Kivu Bioscience–SEVERAL: investment, 202410 financing round Series A $92m led by Novo Holdings |
2024-10-28 |
Nuclera–SEVERAL: investment, 202410 financing round $75m led by Elevage Medical Technologies (Patient Square Capital) |
2024-10-16 |
Invios–SEVERAL: investment, 202410 financing round Series A €8.2m incl existing investors + Ligand Pharmaceuticals |
2024-10-15 |
Booster Therapeutics–Apollo Health Ventures: investment, 202410 seed financing round totalling $15m incl co-lead investor Apollo Health Ventures |
2024-10-10 |
Booster Therapeutics–Novo Group: investment, 202410 seed financing round totalling $15m incl co-lead investor Novo Holdings |
2024-10-10 |
Booster Therapeutics–SEVERAL: investment, 202410 seed financing round $15m led by Apollo Health Ventures + Novo Holdings |
2024-10-10 |
Immatics–SEVERAL: investment, 202410– proposed public offering $150m |
2024-10-10 |
Lumicks–EU (govt): credit, 202410– venture debt financing €20m from EIB to advance high-througput cell avidity platform |
2024-10-10 |
a:head bio–SEVERAL: investment, 202410 financing round pre-Series A 7-digit EUR from existing + new investors |
2024-10-09 |
Clock Bio–BY Capital: investment, 202410 seed financing round totalling $5.3m incl co-investor BlueYard Capital |
2024-10-09 |
Clock Bio–Onsight Ventures: investment, 202410 seed financing round totalling $5.3m incl co-investor Onsight Ventures |
2024-10-09 |
Clock Bio–PERSON: investment, 202410 seed financing round totalling $5.3m incl co-investor Jonathan Milner |
2024-10-09 |
Clock Bio–Phoenix Court Group: investment, 202410 seed financing round totalling $5.3m incl lead investor LocalGlobe |
2024-10-09 |
Clock Bio–SEVERAL: investment, 202410 seed financing round $5.3m led by LocalGlobe |
2024-10-09 |
Purespring Therapeutics–ICR: public relations, 202410 service existent ICR Consilium is media contact |
2024-10-09 |
Purespring Therapeutics–SEVERAL: investment, 202410 financing round Series B £80m led by Sofinnova Partners |
2024-10-09 |
Bayer–Moma Therapeutics: drug discovery, 202410– collab + excl license option €na using KNOMTIC platform to discover small-molecule cancer drugs |
2024-10-08 |
Lymphatica Medtech–SEVERAL: investment, 202410 financing round Series B €17.9m led by Panakès Partners + TechWald Next + CDP VC |
2024-10-08 |
Somagenetix–MC Services: public relations, 202410 service existent by MC Services |
2024-10-08 |
Somagenetix–Schroders: investment, 202410 financing round Series A totalling CHF10m first closing incl existing + co-investor Schroders Capital |
2024-10-08 |
Somagenetix–SEVERAL: investment, 202410 financing round Series A CHF10m first closing led by Vi Partners |
2024-10-08 |
Somagenetix–Verve Capital Partners: investment, 202410 financing round Series A totalling CHF10m first closing incl existing + co-investor Verve |
2024-10-08 |
Somagenetix–Vi Partners: investment, 202410 financing round Series A totalling CHF10m first closing incl lead investor Vi Partners |
2024-10-08 |
Somagenetix–Zürcher Kantonalbank: investment, 202410 financing round Series A totalling CHF10m first closing incl existing + co-investor ZKB |
2024-10-08 |
Yumab–Molcure: AI-based drug discovery, 202410– collab expansion to incl zero-shot AI Ab discovery technology to discover Abs for undrugged targets |
2024-10-08 |
Danaher–CrestOptics: spinning disk microscopy, 202410– collab integration of Cicero spinning disk unit into Thunder Imager of Leica Microsystems |
2024-10-07 |
Enara Bio–Francis Crick Institute: investment, 202410 financing round Series B totalling $32.5m incl new + co-investor Francis Crick Institute |
2024-10-03 |
Enara Bio–Merck (DE): investment, 202410 financing round Series B totalling $32.5m incl new + co-lead investor M Ventures |
2024-10-03 |
Enara Bio–Pfizer: investment, 202410 financing round Series B totalling $32.5m incl new + co-lead investor Pfizer Ventures |
2024-10-03 |
Enara Bio–RA Capital: investment, 202410 financing round Series B totalling $32.5m incl existing + co-investor RA Capital |
2024-10-03 |
Enara Bio–Samsara BioCapital: investment, 202410 financing round Series B totalling $32.5m incl existing + co-investor Samsara BioCapital |
2024-10-03 |
Enara Bio–SEVERAL: investment, 202410 financing round Series B $32.5m co-led by new investors Pfizer Ventures + M Ventures |
2024-10-03 |
Enara Bio–SV Health Investors: investment, 202410 financing round Series B totalling $32.5m incl existing + co-investor SV Health Investors |
2024-10-03 |
Kurma–SEVERAL: investment, 202410 first closing of Kurma Biofund IV with target for final closing of €250m |
2024-10-03 |
Dynamic Biosensors–Bruker: investment, 202410 acquisition €na of Dynamic Biosensors GmbH + integration in Bruker Biosensors business |
2024-10-02 |
LoQus23 Therapeutics–Forbion: investment, 202410 financing round Series A totalling £35m incl new + lead investor Forbion |
2024-10-02 |
LoQus23 Therapeutics–Novartis: investment, 202410 financing round Series A totalling £35m incl existing + co-investor Novartis Venture Fund |
2024-10-02 |
LoQus23 Therapeutics–Optimum Strategic Communications: public relations, 202410 service existent by Optimum |
2024-10-02 |
LoQus23 Therapeutics–SEVERAL: investment, 202410 financing round Series A £35m led by new investor Forbion |
2024-10-02 |
LoQus23 Therapeutics–SV Health Investors: investment, 202410 financing round Series A totalling £35m incl existing + co-investor DDF |
2024-10-02 |
Aitiologic–Austria (govt): grant, 202306–202410 grants from aws + FFG |
2024-10-01 |
Aitiologic–Lana Ventures: investment, 202306–202410 seed financing round incl co-lead investor LANA Ventures |
2024-10-01 |
Aitiologic–Push Ventures: investment, 202306–202410 seed financing round incl co-lead investor PUSH VC |
2024-10-01 |
Aitiologic–SEVERAL: investment, 202306–202410 seed financing round >€2.5m (incl aws + FFG grants) led by Push VC + Lana Ventures |
2024-10-01 |
Erbe Elektromedizin–1BillionLives: quality management software, 202409 supply existent Erbe is customer of Flinn.ai |
2024-09-30 |
Roche–Regor: CDK inhibitors, 202409– acquisition $850m cash upfront + milestones of portfolio of CDK inhibitors by Genentech from Regor |
2024-09-30 |
Sequentia Biotech–BPCE: investment, 202409 financing round Series A totalling €10m incl lead investor Seventure Partners |
2024-09-27 |
Sequentia Biotech–EU (govt): investment, 202409 financing round Series A totalling €10m incl co-investor EIC Fund |
2024-09-27 |
Sequentia Biotech–SEVERAL: investment, 202409 financing round Series A €10m with Seventure Partners + EIC Fund |
2024-09-27 |
Novo Group–Evotec: cell therapy manufacturing, 202409– collab technology development €na RnD funding + upfront + milestone payments plus royalties |
2024-09-26 |
Resonac–Altaris: investment, 202409– acquisition 100% of Minaris Regenerative Medicine Subsidiaries of Resonac by Altaris LLC |
2024-09-26 |
Genespire–Indaco: investment, 202409 financing round Series B totalling €46.6m incl co-investor Indaco SGR |
2024-09-25 |
Genespire–Italy (govt): investment, 202409 financing round Series B totalling €46.6m incl co-lead investor CDP Venture Capital Large Venture Fund |
2024-09-25 |
Genespire–SEVERAL: investment, 202409 financing round Series B €46.6m led by Sofinnova Partners + Xgen Venture + CDP Venture Capital |
2024-09-25 |
Genespire–Sofinnova: investment, 202409 financing round Series B totalling €46.6m incl existing + co-lead investor Sofinnova Partners |
2024-09-25 |
Genespire–Xgen Venture: investment, 202409 financing round Series B totalling €46.6m incl co-lead investor Xgen Venture |
2024-09-25 |
Constructive Biology–SEVERAL: investment, 202409 financing round Series A first closing $58m led by Ahren + OMX Ventures + Paladin Capital |
2024-09-24 |
Lift BioSciences–SEVERAL: investment, 202409 financing round Series A first closing £10m |
2024-09-24 |
Shan Foods–Symrise: foods, 202409 strategic collab existent Pakistan + UAE + KSA incl joint production plant in Pakistan |
2024-09-20 |
Noah Labs–Adesso: investment, 202409 seed financing round totalling less than €3m incl co-investor Adesso Ventures |
2024-09-19 |
Noah Labs–Berlin (govt): investment, 202409 seed financing round totalling less than €3m incl co-investor DHZB Foundation |
2024-09-19 |
Noah Labs–Brandenburg (govt): credit, 202409 loan from ILB ProFit Brandenburg funding programme |
2024-09-19 |
Noah Labs–Brandenburg (govt): grant, 202409 grant from ILB ProFit Brandenburg funding programme |
2024-09-19 |
Noah Labs–Nina Capital: investment, 202409 seed financing round totalling less than €3m incl lead investor Nina Capital |
2024-09-19 |
Noah Labs–OTHER: investment, 202409 seed financing round totalling less than €3m incl range of business angels |
2024-09-19 |
Noah Labs–SEVERAL: investment, 202409 seed financing round €3m (incl grant + loan from ILB) led by Nina Capital |
2024-09-19 |
Austrian Academy of Sciences–Boehringer: grant, 202409–203608 funding €150m establishment + operation of AITHYRA Institute over 12y by BIS |
2024-09-18 |
Roivant–Organon: investment, 202409– acquisition of Dermavant Sciences by Organon $175m upfront + $1.025b milestones plus royalties incl product Vtama |
2024-09-18 |
ImmunOs Therapeutics–BioMedPartners: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor BioMed Partners |
2024-09-17 |
ImmunOs Therapeutics–Double Point Ventures: investment, 202409 financing round Series C totalling $11m incl new + co-investor Double Point Ventures |
2024-09-17 |
ImmunOs Therapeutics–Gimv: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor Gimv |
2024-09-17 |
ImmunOs Therapeutics–Mission BioCapital: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor Mission BC |
2024-09-17 |
ImmunOs Therapeutics–Pfizer: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor Pfizer Ventures |
2024-09-17 |
ImmunOs Therapeutics–SEVERAL: investment, 202409 financing round Series C $11m led by Gimv + Pfizer Ventures ü+ Mission BioCapital + BioMedPartners |
2024-09-17 |
Trials24–Subject Well: investment, 202409 acquisition of Trials24 by SubjectWell backed by PE firm WindRose Health |
2024-09-17 |
Cell Signaling Technology–e-Blot Life Science: imaging system, 202409– distribution of Touch Imager system by Bioké in 12 European countries |
2024-09-16 |
Symphera–Bavaria (govt): investment, 202409 seed financing round totalling €2.4m incl co-investor HTGF |
2024-09-16 |
Symphera–Carma Fund: investment, 202409 seed financing round totalling €2.4m incl co-investor Carma Fund |
2024-09-16 |
Symphera–High-Tech Gründerfonds: investment, 202409 seed financing round totalling €2.4m incl lead investor HTGF |
2024-09-16 |
Symphera–IRCAD: investment, 202409 seed financing round totalling €2.4m incl co-investor IRCAD Strasbourg |
2024-09-16 |
Symphera–OTHER: investment, 202409 seed financing round totalling €2.4m incl expert business angels from the medical field |
2024-09-16 |